首页 > 最新文献

Antimicrobial stewardship & healthcare epidemiology : ASHE最新文献

英文 中文
An outbreak after all: Cutibacterium acnes among pediatric patients with cerebrospinal fluid diversion device infections highlights gaps in guidelines. 疫情终究还是爆发了:脑脊液分流装置感染的儿科患者中的痤疮切迹杆菌凸显了指南中的不足。
Pub Date : 2024-09-12 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.359
Felicia Scaggs Huang, Cameron Griffin, Matthew Fenchel, Melanie DuBose, Andrea Ankrum, Joshua K Schaffzin

Objective: Cutibacterium acnes is normal skin flora but can cause sterile implant infections. We investigated a cluster of seven patients with C. acnes in anaerobic cerebrospinal fluid (CSF) cultures in November 2020. Further analysis identified a missed outbreak, highlighting ambiguity in diagnosis of indolent organisms in the 2017 IDSA meningitis guidelines.

Design: Outbreak investigation.

Setting: Quaternary pediatric facility.

Patients: A case was defined as a hospitalized patient with C. acnes isolated from CSF culture from January 1, 2016 to December 31, 2022.

Methods: We defined comparison periods based on timing of C. acnes culture positivity as 1) pre-outbreak (2016-2020), 2) outbreak (2020-2021), and 3) post-outbreak (2022). Rates of C. acnes positive cultures per 1000 CSF cultures and rate ratios were calculated by comparison periods.

Results: We identified 9 positive C. acnes CSF cultures among 7 cases November 10-27, 2020, all with at least 1 CSF diversion device. The anaerobic culture media was substituted at the time of case cluster. In 2021, the culture media was implemented permanently with no increase in C. acnes culture positivity. The rate of C. acnes positive CSF cultures and rate ratio increased in the outbreak period (p=0.01) compared to pre-outbreak and post-outbreak periods. There was no difference between the pre- and post-outbreak periods.

Conclusions: Retrospective analysis of CSF culture data led to reclassifying a C. acnes pseudo-outbreak as a true outbreak in CSF diversion devices at our institution. Clearer guidance is needed to delineate the role of C. acnes in CSF diversion device infections.

目的:痤疮丙酸杆菌是正常的皮肤菌群,但可引起无菌植入感染。我们对 2020 年 11 月在厌氧性脑脊液(CSF)培养中检出痤疮丙酸杆菌的七名患者进行了调查。进一步分析发现了一个漏报的疫情,突出了2017年IDSA脑膜炎指南中对不耐药菌诊断的模糊性:设计:疫情调查:病例病例定义为2016年1月1日至2022年12月31日期间从CSF培养中分离出痤疮丙酸杆菌的住院患者:我们根据痤疮丙酸杆菌培养阳性的时间将比较期定义为:1)疫情爆发前(2016-2020 年);2)疫情爆发期(2020-2021 年);3)疫情爆发后(2022 年)。按比较期计算每 1000 份 CSF 培养物中痤疮丙酸杆菌阳性率和比率:我们在 2020 年 11 月 10 日至 27 日的 7 个病例中发现了 9 例痤疮丙酸杆菌 CSF 培养阳性病例,所有病例都至少有一个 CSF 分流装置。在病例集群时,厌氧培养基被替换。2021 年,该培养基被永久性使用,痤疮丙酸杆菌培养阳性率没有增加。与疫情爆发前和疫情爆发后相比,痤疮丙酸杆菌培养阳性率和比率在疫情爆发期间有所上升(p=0.01)。疫情爆发前和爆发后没有差异:对 CSF 培养数据的回顾性分析导致本机构将痤疮丙酸杆菌假性疫情重新归类为 CSF 转流装置中的真正疫情。需要更明确的指导来界定痤疮丙酸杆菌在脑脊液分流装置感染中的作用。
{"title":"An outbreak after all: <i>Cutibacterium acnes</i> among pediatric patients with cerebrospinal fluid diversion device infections highlights gaps in guidelines.","authors":"Felicia Scaggs Huang, Cameron Griffin, Matthew Fenchel, Melanie DuBose, Andrea Ankrum, Joshua K Schaffzin","doi":"10.1017/ash.2024.359","DOIUrl":"https://doi.org/10.1017/ash.2024.359","url":null,"abstract":"<p><strong>Objective: </strong><i>Cutibacterium acnes</i> is normal skin flora but can cause sterile implant infections. We investigated a cluster of seven patients with <i>C. acnes</i> in anaerobic cerebrospinal fluid (CSF) cultures in November 2020. Further analysis identified a missed outbreak, highlighting ambiguity in diagnosis of indolent organisms in the 2017 IDSA meningitis guidelines.</p><p><strong>Design: </strong>Outbreak investigation.</p><p><strong>Setting: </strong>Quaternary pediatric facility.</p><p><strong>Patients: </strong>A case was defined as a hospitalized patient with <i>C. acnes</i> isolated from CSF culture from January 1, 2016 to December 31, 2022.</p><p><strong>Methods: </strong>We defined comparison periods based on timing of <i>C. acnes</i> culture positivity as 1) pre-outbreak (2016-2020), 2) outbreak (2020-2021), and 3) post-outbreak (2022). Rates of <i>C. acnes</i> positive cultures per 1000 CSF cultures and rate ratios were calculated by comparison periods.</p><p><strong>Results: </strong>We identified 9 positive <i>C. acnes</i> CSF cultures among 7 cases November 10-27, 2020, all with at least 1 CSF diversion device. The anaerobic culture media was substituted at the time of case cluster. In 2021, the culture media was implemented permanently with no increase in <i>C. acnes</i> culture positivity. The rate of <i>C. acnes</i> positive CSF cultures and rate ratio increased in the outbreak period (p=0.01) compared to pre-outbreak and post-outbreak periods. There was no difference between the pre- and post-outbreak periods.</p><p><strong>Conclusions: </strong>Retrospective analysis of CSF culture data led to reclassifying a <i>C. acnes</i> pseudo-outbreak as a true outbreak in CSF diversion devices at our institution. Clearer guidance is needed to delineate the role of <i>C. acnes</i> in CSF diversion device infections.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CLABSIs aren't just for inpatients: the need to identify CLABSI burden among outpatients. CLABSI 不只是住院病人的专利:有必要确定门诊病人的 CLABSI 负担。
Pub Date : 2024-09-12 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.384
Opeyemi Oladapo-Shittu, Sara E Cosgrove, Clare Rock, Yea-Jen Hsu, Eili Klein, Anthony D Harris, Carlos Mejia Chew, Heather Saunders, Patrick R Ching, Avi Gadala, Stephanie Mayoryk, Lisa Pineles, Lisa L Maragakis, Alejandra B Salinas, Taylor Helsel, Sara C Keller
{"title":"CLABSIs aren't just for inpatients: the need to identify CLABSI burden among outpatients.","authors":"Opeyemi Oladapo-Shittu, Sara E Cosgrove, Clare Rock, Yea-Jen Hsu, Eili Klein, Anthony D Harris, Carlos Mejia Chew, Heather Saunders, Patrick R Ching, Avi Gadala, Stephanie Mayoryk, Lisa Pineles, Lisa L Maragakis, Alejandra B Salinas, Taylor Helsel, Sara C Keller","doi":"10.1017/ash.2024.384","DOIUrl":"https://doi.org/10.1017/ash.2024.384","url":null,"abstract":"","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review. C 反应蛋白和降钙素原在 COVID-19 患者的抗菌药物管理中是否安全有用?范围界定综述。
Pub Date : 2024-09-12 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.372
Anita Williams, Ernestina Repetto, Ishmael Lebbie, Mohamad Khalife, Tomas Oestergaard Jensen

Objective: The primary objectives of this study were to assess the usefulness of C-reactive protein (CRP) and procalcitonin (PCT) in the diagnosis of bacterial co-infections in coronavirus disease 2019 (COVID-19) and if their incorporation in antimicrobial stewardship (AMS) programs is safe and useful, stratified by severity of disease as level of care, intensive care unit (ICU) or non-ICU. Our secondary objectives were to identify cut-off values for antibiotic decision-making and identify reported results from low- and middle-income countries (LMICs).

Design: A scoping review of published literature, adhering to the PRISMA statement for Systematic Reviews and Meta-analyses Extension for Scoping Reviews guidelines. The last search was performed in January 2024.

Results: Fifty-nine studies were included in this scoping review: 20 studies reporting predictive values and/or sensitivity/specificity results for PCT, 8 reporting clear objectives on AMS, and 3 studies from LMICs.

Conclusion: In the context of non-ICU hospitalized COVID-19 patients in high-income countries, a PCT value below 0.25 mg/L can be a useful tool to rule out bacterial co-infection. The wide range of reported negative predictive values suggests that PCT should be interpreted in the context of other clinical findings. Our results do not support the use of CRP in the same manner as PCT. There is a clear need for more studies in LMICs.

研究目的本研究的主要目的是评估C反应蛋白(CRP)和降钙素原(PCT)在诊断2019年冠状病毒疾病(COVID-19)中的细菌合并感染中的作用,以及将其纳入抗菌药物管理(AMS)计划是否安全和有用。我们的次要目标是确定抗生素决策的临界值,并确定中低收入国家(LMIC)的报告结果:设计:对已发表的文献进行范围界定综述,遵守《系统综述和荟萃分析扩展范围界定综述指南》(PRISMA)声明。最后一次检索于 2024 年 1 月进行:本次范围界定审查共纳入 59 项研究:20项研究报告了PCT的预测值和/或灵敏度/特异性结果,8项研究报告了AMS的明确目标,3项研究来自低收入国家:结论:对于高收入国家非重症监护病房住院的 COVID-19 患者,PCT 值低于 0.25 mg/L 可以作为排除细菌合并感染的有用工具。所报告的阴性预测值范围很广,这表明在解释 PCT 时应结合其他临床结果。我们的研究结果不支持以与 PCT 相同的方式使用 CRP。显然需要在低收入国家开展更多的研究。
{"title":"Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review.","authors":"Anita Williams, Ernestina Repetto, Ishmael Lebbie, Mohamad Khalife, Tomas Oestergaard Jensen","doi":"10.1017/ash.2024.372","DOIUrl":"https://doi.org/10.1017/ash.2024.372","url":null,"abstract":"<p><strong>Objective: </strong>The primary objectives of this study were to assess the usefulness of C-reactive protein (CRP) and procalcitonin (PCT) in the diagnosis of bacterial co-infections in coronavirus disease 2019 (COVID-19) and if their incorporation in antimicrobial stewardship (AMS) programs is safe and useful, stratified by severity of disease as level of care, intensive care unit (ICU) or non-ICU. Our secondary objectives were to identify cut-off values for antibiotic decision-making and identify reported results from low- and middle-income countries (LMICs).</p><p><strong>Design: </strong>A scoping review of published literature, adhering to the PRISMA statement for Systematic Reviews and Meta-analyses Extension for Scoping Reviews guidelines. The last search was performed in January 2024.</p><p><strong>Results: </strong>Fifty-nine studies were included in this scoping review: 20 studies reporting predictive values and/or sensitivity/specificity results for PCT, 8 reporting clear objectives on AMS, and 3 studies from LMICs.</p><p><strong>Conclusion: </strong>In the context of non-ICU hospitalized COVID-19 patients in high-income countries, a PCT value below 0.25 mg/L can be a useful tool to rule out bacterial co-infection. The wide range of reported negative predictive values suggests that PCT should be interpreted in the context of other clinical findings. Our results do not support the use of CRP in the same manner as PCT. There is a clear need for more studies in LMICs.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence. 菲达霉素对艰难梭菌复发高风险患者的实际疗效。
Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.381
Benjamin Colwell, Jennifer Aguilar, Frances Hughes, Pavel Goriacko, Victor Chen, Mei Chang, Rachel Bartash, Yi Guo

Objective: Compare the real-world impact of fidaxomicin (FDX) and vancomycin (VAN) on Clostridioides difficile infection (CDI) recurrence in a high-risk patient population.

Design: A retrospective, matched-cohort study evaluating hospitalized patients with CDI from January 1, 2016, to November 1, 2022, within a tertiary academic medical center.

Patients: Adult patients with at least 1 prior CDI case who received either FDX or VAN for non-fulminant CDI while admitted, and had at least 1 additional risk factor for recurrence. Risk factors included age >70, solid organ or bone marrow transplant recipients, broad-spectrum antibiotic use within 30 days, or receipt of chemotherapy/immune-modulating agents within 30 days of admission. FDX and VAN patients were matched according to risk factors.

Results: A total of 415 patient admissions were identified. After the exclusion of 92 patients for fulminant CDI, diarrhea from another cause, or use of VAN taper therapy, and 15 unmatched patients, 308 patient admissions were included (68 FDX and 240 VAN patients). There were no significant differences in 4-week recurrence (26% vs 23%; OR 1.1; P = .51), 90-day CDI readmission (29% vs 23%; P = .65), or 90-day all-cause readmission (54% vs 53%; P = .91). There was a significant 17% decrease in 90-day mortality associated with the use of FDX (OR .3; P = .04).

Conclusions: In a real-world high-risk patient population, the use of FDX compared to oral VAN did not result in decreased CDI recurrence within 4 weeks or fewer hospital readmissions within 90 days. Further research is needed to better assess the value of FDX in this patient population.

目的:比较菲达霉素(FDX)和万古霉素(VAN)对高危患者群体中艰难梭菌感染(CDI)复发的实际影响:比较菲达霉素(FDX)和万古霉素(VAN)对高风险患者群体中艰难梭菌感染(CDI)复发的实际影响:一项回顾性配对队列研究,评估一家三级学术医疗中心从2016年1月1日至2022年11月1日期间住院的CDI患者:既往至少有一例 CDI 病例的成人患者,入院时接受了 FDX 或 VAN 治疗非重症 CDI,且至少有一个额外的复发风险因素。风险因素包括年龄大于 70 岁、接受过实体器官或骨髓移植、30 天内使用过广谱抗生素或入院后 30 天内接受过化疗/免疫调节药物。根据风险因素对 FDX 和 VAN 患者进行配对:结果:共发现 415 例入院患者。在排除了92名因暴发性CDI、其他原因引起的腹泻或使用VAN减量疗法的患者和15名未配对的患者后,共纳入了308名入院患者(68名FDX患者和240名VAN患者)。4周复发率(26% vs 23%; OR 1.1; P = .51)、90天CDI再入院率(29% vs 23%; P = .65)或90天全因再入院率(54% vs 53%; P = .91)均无明显差异。使用 FDX 后,90 天死亡率大幅下降 17%(OR .3;P = .04):结论:在真实世界的高风险患者群体中,与口服 VAN 相比,使用 FDX 并不能降低 CDI 在 4 周内的复发率或 90 天内的再入院率。需要进一步研究以更好地评估 FDX 在这一患者群体中的价值。
{"title":"Real-world effectiveness of fidaxomicin in patients at high risk of <i>Clostridioides difficile</i> recurrence.","authors":"Benjamin Colwell, Jennifer Aguilar, Frances Hughes, Pavel Goriacko, Victor Chen, Mei Chang, Rachel Bartash, Yi Guo","doi":"10.1017/ash.2024.381","DOIUrl":"https://doi.org/10.1017/ash.2024.381","url":null,"abstract":"<p><strong>Objective: </strong>Compare the real-world impact of fidaxomicin (FDX) and vancomycin (VAN) on <i>Clostridioides difficile</i> infection (CDI) recurrence in a high-risk patient population.</p><p><strong>Design: </strong>A retrospective, matched-cohort study evaluating hospitalized patients with CDI from January 1, 2016, to November 1, 2022, within a tertiary academic medical center.</p><p><strong>Patients: </strong>Adult patients with at least 1 prior CDI case who received either FDX or VAN for non-fulminant CDI while admitted, and had at least 1 additional risk factor for recurrence. Risk factors included age >70, solid organ or bone marrow transplant recipients, broad-spectrum antibiotic use within 30 days, or receipt of chemotherapy/immune-modulating agents within 30 days of admission. FDX and VAN patients were matched according to risk factors.</p><p><strong>Results: </strong>A total of 415 patient admissions were identified. After the exclusion of 92 patients for fulminant CDI, diarrhea from another cause, or use of VAN taper therapy, and 15 unmatched patients, 308 patient admissions were included (68 FDX and 240 VAN patients). There were no significant differences in 4-week recurrence (26% vs 23%; OR 1.1; <i>P</i> = .51), 90-day CDI readmission (29% vs 23%; <i>P</i> = .65), or 90-day all-cause readmission (54% vs 53%; <i>P</i> = .91). There was a significant 17% decrease in 90-day mortality associated with the use of FDX (OR .3; <i>P</i> = .04).</p><p><strong>Conclusions: </strong>In a real-world high-risk patient population, the use of FDX compared to oral VAN did not result in decreased CDI recurrence within 4 weeks or fewer hospital readmissions within 90 days. Further research is needed to better assess the value of FDX in this patient population.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of methicillin-resistant Staphylococcus aureus nasal swab screening at a large comprehensive cancer center. 大型综合癌症中心对耐甲氧西林金黄色葡萄球菌鼻拭子筛查的评估。
Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.370
Mark J Herrington, Chun Feng, Hyunsoo Hwang, Nancy N Vuong

Objective: The aim of this study is to determine the predictive values of MRSA swab screenings in patients with cancer.

Methods: This is a retrospective cohort observational study of adult patients admitted to The University of Texas MD Anderson Cancer Center between January 2019 and October 2022. Data collected from patients with documented MRSA nasal swab screenings and clinical cultures taken within 7 days were collected. The first documented MRSA swab screening and culture results from unique patients were included for analysis to calculate sensitivity, specificity, positive predictive value, and NPV.

Results: A total of 6475 patients with MRSA nasal swab cultures had 13129 clinical cultures from different anatomical sites. Of the patients included, 57% had a solid tumor and 37% had a hematological malignancy, with 82% of patients receiving an anti-MRSA antibiotic prior to MRSA nasal swab. There were 167 documented positive MRSA cultures, most commonly from a wound (41.3%) or respiratory source (24%). Overall sensitivity and specificity for all culture sites were 50.9% and 98.4%, respectively, with an overall NPV of 99.4%. The NPV was 99.8% for bloodstream infections, 98.5% for respiratory infections, 92.6% for wound infections, and greater than 99% for other culture sites.

Conclusion: The specificity and negative predictive value of MRSA swab screenings in patients with cancer was high overall and consistent with the literature in immunocompetent patients. These results may aid in antimicrobial stewardship activities that can help guide the discontinuation of empiric antibiotics in patients with cancer.

研究目的本研究旨在确定癌症患者 MRSA 拭子筛查的预测值:这是一项回顾性队列观察研究,研究对象为 2019 年 1 月至 2022 年 10 月期间入住德克萨斯大学 MD 安德森癌症中心的成年患者。研究收集了 7 天内有 MRSA 鼻拭子筛查记录和临床培养的患者数据。分析中纳入了唯一患者的首次有记录的 MRSA 鼻拭子筛查和培养结果,以计算灵敏度、特异性、阳性预测值和 NPV:结果:共有 6475 名患者进行了 MRSA 鼻拭子培养,13129 次临床培养来自不同的解剖部位。在纳入的患者中,57%患有实体瘤,37%患有血液恶性肿瘤,82%的患者在进行MRSA鼻拭子培养前接受了抗MRSA抗生素治疗。记录在案的 MRSA 培养阳性病例有 167 例,最常见的病例来自伤口(41.3%)或呼吸道(24%)。所有培养部位的总体敏感性和特异性分别为 50.9% 和 98.4%,总体 NPV 为 99.4%。血流感染的 NPV 为 99.8%,呼吸道感染为 98.5%,伤口感染为 92.6%,其他培养部位的 NPV 均大于 99%:癌症患者MRSA拭子筛查的特异性和阴性预测值总体较高,与免疫功能正常患者的文献报道一致。这些结果可能有助于开展抗菌药物管理活动,从而指导癌症患者停止使用经验性抗生素。
{"title":"Evaluation of methicillin-resistant <i>Staphylococcus aureus</i> nasal swab screening at a large comprehensive cancer center.","authors":"Mark J Herrington, Chun Feng, Hyunsoo Hwang, Nancy N Vuong","doi":"10.1017/ash.2024.370","DOIUrl":"https://doi.org/10.1017/ash.2024.370","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to determine the predictive values of MRSA swab screenings in patients with cancer.</p><p><strong>Methods: </strong>This is a retrospective cohort observational study of adult patients admitted to The University of Texas MD Anderson Cancer Center between January 2019 and October 2022. Data collected from patients with documented MRSA nasal swab screenings and clinical cultures taken within 7 days were collected. The first documented MRSA swab screening and culture results from unique patients were included for analysis to calculate sensitivity, specificity, positive predictive value, and NPV.</p><p><strong>Results: </strong>A total of 6475 patients with MRSA nasal swab cultures had 13129 clinical cultures from different anatomical sites. Of the patients included, 57% had a solid tumor and 37% had a hematological malignancy, with 82% of patients receiving an anti-MRSA antibiotic prior to MRSA nasal swab. There were 167 documented positive MRSA cultures, most commonly from a wound (41.3%) or respiratory source (24%). Overall sensitivity and specificity for all culture sites were 50.9% and 98.4%, respectively, with an overall NPV of 99.4%. The NPV was 99.8% for bloodstream infections, 98.5% for respiratory infections, 92.6% for wound infections, and greater than 99% for other culture sites.</p><p><strong>Conclusion: </strong>The specificity and negative predictive value of MRSA swab screenings in patients with cancer was high overall and consistent with the literature in immunocompetent patients. These results may aid in antimicrobial stewardship activities that can help guide the discontinuation of empiric antibiotics in patients with cancer.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social and ecological determinants of antimicrobial resistance in Africa: a systematic review of epidemiological evidence. 非洲抗菌药耐药性的社会和生态决定因素:流行病学证据系统回顾。
Pub Date : 2024-09-09 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.375
Catherine Bennett, Will Russel, Rebecca Upton, Frank Frey, Bineyam Taye

Background: Antimicrobial resistance (AMR) is one of the greatest global health problems for humans, animals, and the environment. Although the association between various factors and AMR is being increasingly researched, the need to understand the contribution of social and ecological determinants, especially in developing nations, remains. This review fills these knowledge gaps by synthesizing existing evidence on the social and ecological determinants of AMR in Africa.

Results: Twenty-four studies were selected based on predefined criteria from PubMed. 58.33% (n = 14) and 29.17% (n = 7) of the studies reported on ecological and social determinants of AMR, respectively, and 3 (12.5%) studies documented both social and environmental determinants of AMR. Sociodemographic factors include increased household size, poor knowledge, attitudes toward AMR, low educational levels, and rural residences. Indicators of poor water sanitation and hygiene, framing practices, and consumption of farm products were among the common ecological determinants of AMR and AM misuse in Africa.

Conclusion: Our review demonstrates the importance of social and ecological determinants of AMR among African populations. The findings may be valuable to researchers, policymakers, clinicians, and those working in lower-income countries to implement AMR prevention programs utilizing a holistic approach.

背景:抗菌素耐药性(AMR)是人类、动物和环境面临的最大全球健康问题之一。尽管对各种因素与 AMR 之间关系的研究越来越多,但人们仍然需要了解社会和生态决定因素的作用,尤其是在发展中国家。本综述通过综合非洲 AMR 社会和生态决定因素的现有证据,填补了这些知识空白:根据预先设定的标准,从 PubMed 中筛选出 24 项研究。58.33%(n = 14)和 29.17%(n = 7)的研究分别报告了 AMR 的生态和社会决定因素,3 项(12.5%)研究同时记录了 AMR 的社会和环境决定因素。社会人口因素包括家庭人口增加、知识贫乏、对 AMR 的态度、教育水平低和居住在农村。在非洲,不良的水质卫生和个人卫生指标、框架做法和农产品消费是导致 AMR 和 AM 滥用的常见生态决定因素:我们的综述表明了非洲人口中AMR的社会和生态决定因素的重要性。这些发现对研究人员、政策制定者、临床医生以及在低收入国家工作的人员利用整体方法实施AMR预防计划很有价值。
{"title":"Social and ecological determinants of antimicrobial resistance in Africa: a systematic review of epidemiological evidence.","authors":"Catherine Bennett, Will Russel, Rebecca Upton, Frank Frey, Bineyam Taye","doi":"10.1017/ash.2024.375","DOIUrl":"https://doi.org/10.1017/ash.2024.375","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) is one of the greatest global health problems for humans, animals, and the environment. Although the association between various factors and AMR is being increasingly researched, the need to understand the contribution of social and ecological determinants, especially in developing nations, remains. This review fills these knowledge gaps by synthesizing existing evidence on the social and ecological determinants of AMR in Africa.</p><p><strong>Results: </strong>Twenty-four studies were selected based on predefined criteria from PubMed. 58.33% (n = 14) and 29.17% (n = 7) of the studies reported on ecological and social determinants of AMR, respectively, and 3 (12.5%) studies documented both social and environmental determinants of AMR. Sociodemographic factors include increased household size, poor knowledge, attitudes toward AMR, low educational levels, and rural residences. Indicators of poor water sanitation and hygiene, framing practices, and consumption of farm products were among the common ecological determinants of AMR and AM misuse in Africa.</p><p><strong>Conclusion: </strong>Our review demonstrates the importance of social and ecological determinants of AMR among African populations. The findings may be valuable to researchers, policymakers, clinicians, and those working in lower-income countries to implement AMR prevention programs utilizing a holistic approach.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Situations predisposing primary care patients to use antibiotics without a prescription in the United States. 美国初级保健患者容易在没有处方的情况下使用抗生素的情况。
Pub Date : 2024-09-09 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.361
Lindsey A Laytner, Barbara W Trautner, Susan Nash, Fabrizia Faustinella, Roger Zoorob, Kiara Olmeda, Michael K Paasche-Orlow, Larissa Grigoryan

Background: Patients' situations can impact their intentions to use antibiotics without medical guidance (non-prescription use) in the future. This survey determines the prevalence of intended (future) use of non-prescription antibiotics for 13 predefined situations and identifies the sociodemographic characteristics associated with intended use for these types of situations.

Methods: Patient surveys (N = 564) were conducted from January 2020 to June 2021 in the waiting rooms of 6 safety-net primary care clinics and 2 emergency departments in a private healthcare system. We used principal component analysis to identify 3 situational summary factors: barriers to a doctor visit, accessibility of non-prescription antibiotics, and previous symptom relief with antibiotics. Multivariate linear regression identified the sociodemographic predictors associated with each summary factor.

Results: The most common situations triggering patients to use non-prescription antibiotics were a perceived high cost of doctor visits (29.8%), having leftover prescription antibiotics (50.4%), and experiencing symptom relief with prior use of antibiotics (47.5%). Multivariate regression results revealed that younger patients (P < 0.04) and patients attending the safety-net health system (P < 0.001) had more intended use of non-prescription antibiotics for all 3 summary factors.

Conclusions: Future stewardship interventions should consider the types of situations that drive patients' decisions to use antibiotics without a prescription. Interventions aimed at reducing barriers to health care (eg, high costs and long waits associated with doctor appointments) and educating individuals on medically appropriate, nonantibiotic treatment options may reduce antibiotic use and antimicrobial resistance.

背景:患者的情况会影响他们将来在没有医疗指导的情况下使用抗生素(非处方药使用)的意愿。本调查确定了 13 种预定情况下打算(未来)使用非处方抗生素的流行率,并确定了与这些情况下打算使用抗生素相关的社会人口特征:2020 年 1 月至 2021 年 6 月,我们在一家私立医疗系统的 6 家安全网初级保健诊所和 2 家急诊科的候诊室进行了患者调查(N = 564)。我们使用主成分分析法确定了 3 个情境总结因素:就医障碍、非处方药抗生素的可及性以及之前使用抗生素缓解症状的情况。多变量线性回归确定了与每个简要因素相关的社会人口学预测因素:引发患者使用非处方药抗生素的最常见情况是认为看病贵(29.8%)、有剩余的处方药抗生素(50.4%)和以前使用抗生素后症状缓解(47.5%)。多变量回归结果显示,年轻患者(P < 0.04)和在安全网医疗系统就诊的患者(P < 0.001)在所有 3 个综合因素中更倾向于使用非处方药抗生素:结论:未来的管理干预措施应考虑促使患者决定无处方使用抗生素的情况类型。旨在减少医疗障碍(如高昂的费用和漫长的就诊等待)的干预措施,以及向个人宣传医学上适当的非抗生素治疗方案,可能会减少抗生素的使用和抗菌药的耐药性。
{"title":"Situations predisposing primary care patients to use antibiotics without a prescription in the United States.","authors":"Lindsey A Laytner, Barbara W Trautner, Susan Nash, Fabrizia Faustinella, Roger Zoorob, Kiara Olmeda, Michael K Paasche-Orlow, Larissa Grigoryan","doi":"10.1017/ash.2024.361","DOIUrl":"https://doi.org/10.1017/ash.2024.361","url":null,"abstract":"<p><strong>Background: </strong>Patients' situations can impact their intentions to use antibiotics without medical guidance (non-prescription use) in the future. This survey determines the prevalence of intended (future) use of non-prescription antibiotics for 13 predefined situations and identifies the sociodemographic characteristics associated with intended use for these types of situations.</p><p><strong>Methods: </strong>Patient surveys (N = 564) were conducted from January 2020 to June 2021 in the waiting rooms of 6 safety-net primary care clinics and 2 emergency departments in a private healthcare system. We used principal component analysis to identify 3 situational summary factors: barriers to a doctor visit, accessibility of non-prescription antibiotics, and previous symptom relief with antibiotics. Multivariate linear regression identified the sociodemographic predictors associated with each summary factor.</p><p><strong>Results: </strong>The most common situations triggering patients to use non-prescription antibiotics were a perceived high cost of doctor visits (29.8%), having leftover prescription antibiotics (50.4%), and experiencing symptom relief with prior use of antibiotics (47.5%). Multivariate regression results revealed that younger patients (<i>P</i> < 0.04) and patients attending the safety-net health system (<i>P</i> < 0.001) had more intended use of non-prescription antibiotics for all 3 summary factors.</p><p><strong>Conclusions: </strong>Future stewardship interventions should consider the types of situations that drive patients' decisions to use antibiotics without a prescription. Interventions aimed at reducing barriers to health care (eg, high costs and long waits associated with doctor appointments) and educating individuals on medically appropriate, nonantibiotic treatment options may reduce antibiotic use and antimicrobial resistance.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel approach for safe and automated implementation of far ultraviolet-C light decontamination in clinical areas. 在临床领域安全自动实施远紫外线-C 光净化的新方法。
Pub Date : 2024-09-09 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.388
Samir Memic, Jennifer L Cadnum, Andrew Osborne, William A Rutala, Curtis J Donskey

A novel wall-mounted far ultraviolet-C (UV-C) light technology providing automated delivery of far UV-C only when people are not present reduced methicillin-resistant Staphylococcus aureus in a patient room and equipment room. The safety feature that discontinues far UV-C output when people are detected was effective in preventing far UV-C exposure.

一种新型壁挂式远紫外线-C(UV-C)灯技术仅在无人时自动输出远紫外线-C,从而减少了病房和设备间中的耐甲氧西林金黄色葡萄球菌。当检测到有人时停止远紫外线-C 输出的安全功能可有效防止远紫外线-C 暴露。
{"title":"A novel approach for safe and automated implementation of far ultraviolet-C light decontamination in clinical areas.","authors":"Samir Memic, Jennifer L Cadnum, Andrew Osborne, William A Rutala, Curtis J Donskey","doi":"10.1017/ash.2024.388","DOIUrl":"https://doi.org/10.1017/ash.2024.388","url":null,"abstract":"<p><p>A novel wall-mounted far ultraviolet-C (UV-C) light technology providing automated delivery of far UV-C only when people are not present reduced methicillin-resistant <i>Staphylococcus aureus</i> in a patient room and equipment room. The safety feature that discontinues far UV-C output when people are detected was effective in preventing far UV-C exposure.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Procedural risk factors for deep and organ/space surgical site infection post-coronary artery bypass graft surgery. 冠状动脉旁路移植手术后深部和器官/间隙手术部位感染的手术风险因素。
Pub Date : 2024-09-09 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.374
Abarna Pearl, Patrick S Gordon, Baevin S Feeser, Dana E Pepe, Preeti Mehrotra, Sharon B Wright

In this study, we examined the impact of the number and type of arterial grafts, and surgical dressing type, on deep and organ/space surgical site infection following coronary artery bypass graft procedures. Bilateral internal mammary artery grafts and negative pressure wound therapy were associated with higher odds of infection.

在这项研究中,我们探讨了动脉移植物的数量和类型以及手术敷料类型对冠状动脉旁路移植术后深部和器官/间隙手术部位感染的影响。双侧乳内动脉移植物和负压伤口疗法与较高的感染几率相关。
{"title":"Procedural risk factors for deep and organ/space surgical site infection post-coronary artery bypass graft surgery.","authors":"Abarna Pearl, Patrick S Gordon, Baevin S Feeser, Dana E Pepe, Preeti Mehrotra, Sharon B Wright","doi":"10.1017/ash.2024.374","DOIUrl":"https://doi.org/10.1017/ash.2024.374","url":null,"abstract":"<p><p>In this study, we examined the impact of the number and type of arterial grafts, and surgical dressing type, on deep and organ/space surgical site infection following coronary artery bypass graft procedures. Bilateral internal mammary artery grafts and negative pressure wound therapy were associated with higher odds of infection.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic utilization trends in Veterans Affairs patients with Stenotrophomonas maltophilia bloodstream infections. 退伍军人事务部嗜麦芽单胞菌血流感染患者的抗生素使用趋势。
Pub Date : 2024-09-09 eCollection Date: 2024-01-01 DOI: 10.1017/ash.2024.364
Clara H Lee, Ursula C Patel, Amanda Vivo, Lishan Cao, Charlesnika T Evans

Objective: Stenotrophomonas maltophilia is a multidrug-resistant gram-negative bacillus that can cause serious infections but has limited treatment options. This study aims to establish trends in the treatment of S. maltophilia bloodstream infections (BSI) across the United States in Department of Veterans Affairs (VA) facilities.

Methods: Data was evaluated over a 10-year timeframe (2012 to 2021) in this retrospective cohort study. Veterans with ≥ 1 blood culture with S. maltophilia within a VA medical encounter were included. Microbiology, pharmacy, and patient information were collected through national VA data sources and chart review. Descriptive statistics and Poisson regression were used to summarize patient demographics, facility characteristics, microbiologic data, and treatment trends.

Results: A total of 374 blood cultures positive for S. maltophilia were identified across 75 VA facilities. Of 282 unique patients with BSI, the majority were male (93.6%), white (67.4%), with a mean age of 64 ± 13.1 years. Of those patients, 78% received treatment, 12.8% had a polymicrobial blood culture, and 5.3% had a documented sulfa allergy. Susceptibility results were most reported for trimethoprim-sulfamethoxazole (TMP-SMX), levofloxacin, and ceftazidime, with 4.5%, 4.3%, and 44.4% resistant isolates, respectively. Antibiotics most prescribed included TMP-SMX (41.5%) and levofloxacin (39.4%), followed by ciprofloxacin (13.8%) and ceftazidime (12.4%). Combination therapy was prescribed in 33% of patients. No significant trends were found with antibiotic utilization over time.

Conclusions: TMP-SMX and levofloxacin were the most prescribed antibiotics for S. maltophilia BSI treatment. No significant changes were seen with antibiotic prescribing trends in Veterans from 2012 to 2021.

目的:嗜麦芽血单胞菌是一种具有多重耐药性的革兰氏阴性杆菌,可引起严重感染,但治疗方法有限。本研究旨在确定美国退伍军人事务部(VA)设施中嗜麦芽单胞菌血流感染(BSI)的治疗趋势:在这项回顾性队列研究中,对 10 年内(2012 年至 2021 年)的数据进行了评估。研究对象包括在退伍军人事务部医疗机构就诊期间嗜麦芽酵母菌血液培养≥1次的退伍军人。通过退伍军人事务部的国家数据源和病历审查收集了微生物学、药学和患者信息。利用描述性统计和泊松回归总结了患者人口统计学特征、设施特征、微生物学数据和治疗趋势:结果:在 75 个退伍军人机构中,共发现 374 例嗜麦芽汁酵母菌血培养阳性病例。在 282 例 BSI 患者中,大多数为男性(93.6%)和白人(67.4%),平均年龄为 64 ± 13.1 岁。其中 78% 的患者接受了治疗,12.8% 的患者进行了多菌血液培养,5.3% 的患者有磺胺过敏记录。报告最多的药敏结果是三甲双胍-磺胺甲恶唑(TMP-SMX)、左氧氟沙星和头孢他啶,耐药分离率分别为 4.5%、4.3% 和 44.4%。处方最多的抗生素包括TMP-SMX(41.5%)和左氧氟沙星(39.4%),其次是环丙沙星(13.8%)和头孢他啶(12.4%)。33%的患者接受了联合治疗。随着时间的推移,抗生素的使用未发现明显趋势:结论:TMP-SMX 和左氧氟沙星是治疗嗜麦芽糖酵母菌 BSI 的最常用抗生素。从 2012 年到 2021 年,退伍军人的抗生素处方趋势没有明显变化。
{"title":"Antibiotic utilization trends in Veterans Affairs patients with <i>Stenotrophomonas maltophilia</i> bloodstream infections.","authors":"Clara H Lee, Ursula C Patel, Amanda Vivo, Lishan Cao, Charlesnika T Evans","doi":"10.1017/ash.2024.364","DOIUrl":"https://doi.org/10.1017/ash.2024.364","url":null,"abstract":"<p><strong>Objective: </strong><i>Stenotrophomonas maltophilia</i> is a multidrug-resistant gram-negative bacillus that can cause serious infections but has limited treatment options. This study aims to establish trends in the treatment of <i>S. maltophilia</i> bloodstream infections (BSI) across the United States in Department of Veterans Affairs (VA) facilities.</p><p><strong>Methods: </strong>Data was evaluated over a 10-year timeframe (2012 to 2021) in this retrospective cohort study. Veterans with ≥ 1 blood culture with <i>S. maltophilia</i> within a VA medical encounter were included. Microbiology, pharmacy, and patient information were collected through national VA data sources and chart review. Descriptive statistics and Poisson regression were used to summarize patient demographics, facility characteristics, microbiologic data, and treatment trends.</p><p><strong>Results: </strong>A total of 374 blood cultures positive for <i>S. maltophilia</i> were identified across 75 VA facilities. Of 282 unique patients with BSI, the majority were male (93.6%), white (67.4%), with a mean age of 64 ± 13.1 years. Of those patients, 78% received treatment, 12.8% had a polymicrobial blood culture, and 5.3% had a documented sulfa allergy. Susceptibility results were most reported for trimethoprim-sulfamethoxazole (TMP-SMX), levofloxacin, and ceftazidime, with 4.5%, 4.3%, and 44.4% resistant isolates, respectively. Antibiotics most prescribed included TMP-SMX (41.5%) and levofloxacin (39.4%), followed by ciprofloxacin (13.8%) and ceftazidime (12.4%). Combination therapy was prescribed in 33% of patients. No significant trends were found with antibiotic utilization over time.</p><p><strong>Conclusions: </strong>TMP-SMX and levofloxacin were the most prescribed antibiotics for <i>S. maltophilia</i> BSI treatment. No significant changes were seen with antibiotic prescribing trends in Veterans from 2012 to 2021.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Antimicrobial stewardship & healthcare epidemiology : ASHE
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1